Novartis partners with Science 37 to conduct virtual clinical trials

Novartis AG (NYSE:NVS) and Science 37 Inc. (Los Angeles, Calif.) expanded their collaboration and will now conduct virtual Phase II and Phase III clinical studies, moving beyond the feasibility studies of the technology under their original 2016 deal.

Novartis will use Science 37's Network Oriented Research Assistant (NORA) to conduct some or all aspects of the clinical trials at a participant’s home and/or in a local physician’s office, rather than at a central trial site. NORA uses mobile devices and telemedicine services to recruit, monitor and track patients who are enrolled in clinical trials...